Loyola University Chicago

Loyola eCommons
Master's Theses

Theses and Dissertations

1986

Identification of Lactoferrin in the Saliva of Patients with Gingivitis
Hwu-Rang Lin
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_theses
Part of the Dentistry Commons

Recommended Citation
Lin, Hwu-Rang, "Identification of Lactoferrin in the Saliva of Patients with Gingivitis" (1986). Master's
Theses. 3513.
https://ecommons.luc.edu/luc_theses/3513

This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It
has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 1986 Hwu-Rang Lin

UBRARY
LOYOLA UNIVERSITY MEDICAL CENTER

IDENTIFICATION OF LACTOFERRIN IN THE SALIVA OF
PATIENTS WITH GINGIVITIS

by

Hwu-Rang lb.in, B.D.S.

A Thesis Submitted to the Faculty of the Graduate
School of Loyola University of Chicago in Partial
Fulfillment of the Requirements for the Degree of
Master of Science

August
1986

DEDICATION
To my parents and my wife, whose loving, devotion,
encouragement, and sacrifice made this all possible.

ii

ACKNOWLEDGEMENTS

I would like to express my sincere gratitude to the following
people:
Dr. Patrick Toto, thesis director, for his excellent guidance and
encouragement throughout this investigation.
To the rest of the members of my co11111ittee,
Dr. Anthony Gargiulo and Dr. James Hagen for their assistance and
support during this study.
Gratitude and special thanks to Mr. Robert Martinez for his excellent
technical assistance.
To my wife, Marie, for her encouragement, understanding and inspiration
during this phase of my education.

iii

VITA
The author, Hwu-Rang Lin, B.D.S., is the son of Hwu-Zong Lin and
Shou-Ching (Chen) Lin.

He was born in Hsin-Chu, Taiwan, R.O.C. on July 22,

1952.
His elementary and secondary education was obtained in Hsin-Chu,
Taiwan.

In September 1970, he entered Taipei Medical College School of

Dentistry and received his degree of Bachelor of Dental Science in June
1976.
Immediately after he graduated from Taipei Medical College he served
two years in the Anny of the Republic of China as a Second Lieutenant,
Dental Officer (1976-1978).

In May 1978, he was honorably discharged from

the Anny.
After his release from military service, he worked as a teaching
assistant and resident in Taipei Medical College School of Dentistry, Taipei,
Taiwan, until 1982.
On June 23, 1982 he married Marie Chang in Taipei, Taiwan.

In Sep-

tember 1982, he entered Loyola University of Chicago to continue his graduate
dental education leading to a degree of Master of Science in Oral Biology.
In September 1983, he also entered a two year post-graduate clinical specialty in Periodontics.
On September 24, 1984, Jeffery Gee-Jay Lin the first child of Hwu-Rang
and Marie Lin was born.
In May 1985, he received a Certificate of Specialty in Periodontics.
iv

TABLE OF CONTENTS
Page
DEDICATION. . . .

ii

ACKNOWLEDGEMENTS.

iii

VITA.
LIST

.................
OF TABLES. . . . . . . . .
....

CONTENTS OF APPENDICES.

iv

....
....

vi
vii

CHAPTER
I.
II.

........
REVIEW OF LITERATURE. .
.....

2

.

2

INTRODUCTION.

Iron and Infection.

Sources of Lactoferrin.

.

Properties of Lactoferrin

....

.

The Function of Lactoferrin

III.
IV.
V.

....

1

....
....
....

5
9

10

Alteration of Lactoferrin Levels ..

15

Role of Bacteria in Gingivitis . . . .

19

Enzyme-linked Immunosorbent Assay

21

MATERIAL AND METHOD .

24

RESULTS . . . .

29

DISCUSSION ..

40

VI. SUMMARY AND CONCLUSION.
BIBLIOGRAPHY. . •

45

....

APPENDIX

47

55
v

LIST OF TABLES

Table

Page

1.

Gingival Index for the Experimental Group . .

31

2.

Gingival Index for the Control Group . . •

32

3.

Gingival Index (Mean+ S.D.), comparison between
two groups • . . . • . . • . • . . . . .
. . . . . .

33

Probing Pocket Depth (rrvn) for the Experimental
Group. . . . . . . . . . . . . . . . . . . . .

34

5.

Probing Pocket Depth (rrvn) for the Control Group. .

35

6.

Probing Pocket Depth (Mean+ S.D., mm), comparison
between two groups .
. . . . • . . . .

36

Lactoferrin Concentrations (mg%) for the Experimental Group . . . . . . .
. ...... .

37

Lactoferrin Concentrations (mg%) for the Control
Group. • . • • . . . . . .

38

Lactoferrin Concentrations (Mean+ S.D., mg%),
comparison between two groups. • . . . . . . . .

39

4.

7.
8.
9.

vi

CONTENTS OF APPENDICES
Page
Periodontal Charting of Patient #1
Periodontal Charting of Patient #2
Periodontal Charting of Patient #3
Periodontal Charting of Patient #4
Periodontal Charting of Patient #5
Periodontal Charting of Patient #6
Periodontal Charting of Patient #7
Periodontal Charting of Patient #8
Periodontal Charting of Patient #9

.
.
.
.

Periodontal Charting of Patient #10

....
.............
....
........
........
....
..........
....
.....
......
....

56
57
58
59
60
61
62
63
64
65
66

Periodontal Charting of Subject #11
Periodontal Charting of Subject #12
Periodontal Charting of Subject #13 .

........
..........

68
69

Periodontal Charting of Subject #14 .
Periodontal Charting of Subject #15 .

........

Periodontal Charting of Subject #16 •

.....
........
......

Periodontal Charting of Subject #17
Periodontal Charting of Subject #18 •

67

.

Periodontal Charting of Subject #19 •
Periodontal Charting of Subject #20 •
vii

....
......

70
71

72

73
74
75

CHAPTER I
INTRODUCTION
In 1939 a red protein was discovered in bovine milk by Sorensen and
Sorensen.

This protein has been given various names, such as lactoferrin,

lactotransferrin, lactosiderophilin or red milk protein.
Because of its absence in serum, lactoferrin has been regarded as a
specific milk protein.

However, by using inmunological methods it has also

been possible to demonstrate the presence of lactoferrin in various external
fluids.

Elevations in the level of lactoferrin in secretions have been re-

ported in several infectious diseases, such as mastitis, pancreatitis and
salivary gland diseases.

Therefore, lactoferrin might play an important

role in protection of epithelial tissues from infection.
The presence of lactoferrin in saliva suggests that it may be important
in the control of oral disease processes, such as gingivitis, periodontitis
and dental caries.
The purpose of this study was to detennine if there is any differences
in the concentrations of lactoferrin in saliva between patients with gingivitis and clinically healthy individuals without gingivitis, using the enzymelinked inmuno-sorbent assay (ELISA} technique.

Changes in the level of lac-

toferrin after the treatment for the patients with gingivitis was also detennined.
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CHAPTER II
REVIEW OF LITERATURE
Iron and Infection
Iron is required by all living cells, including bacteria. According
to Weinberg (1978), bacteria need approximately 0.4 to 4.0 uM iron for growth.
In the context of bacterial growth in man iron not freely available to microorganisms.

Iron content of an average man is 4.5 gm (Bell et al., 1953). It

is tightly bound to hemoglobin, myoglobin, ferritin and hemosiderin. Although
the total iron concentration in manmalian body fluids is 2 x 10- 5M (Griffiths et al., 1980), almost all of the iron is associated with iron-binding
and transport proteins such as transferrin in plasma and lactoferrin in mucosal secretions. Only 10- 18Mfree-iron is available in body fluids (Bullen
et al, 1978; Bullen et al, 1981). This concentration is far lower than the
bacteria need for growth.

Furthermore, mammals, birds, reptiles and verte-

brates can make metabolic adjustment during infection to withhold the essential iron from invading bacteria.

Such invaded hosts promptly become hypo-

ferrimic by halting intestinal assimilation and by increasing the quantity
in storage of iron in the liver (Weinberg, 1974).
Prior stationing of host iron-binding proteins at potential sites of
bacterial invasion and increased synthesis of host iron-binding proteins are
also two possible antibacterial protective mechanisms (Weinberg, 1978). The
ability of the host to withhold iron from microbes is called "nutritional
2
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immunity".

The term was first used by. Kochan in 1973.

Therefore, it is the

ability of the microbes to acquire the iron essential for their growth and
metabolism that may determine the nature of the host-parasite interactions.
One strategy to obtain iron by the successful pathogens is that they must
rapidly adapt to the low-iron environment.

The successful pathogens produce

powerful iron-chelating agents that can remove iron from iron-binding proteins.

Because of extreme insolubility of ferric ion at neutral pH, aerobic

and facultative microbes can synthesize either phenolates, which are derivatives of 2,3-dihydroxybenzoic acid, or hydroxamates, which are derived from
hydroxamic acid.

Phenolates and hydroxamates in bacteria serve to solubilize

and assimilate the iron.

These compounds are known as

11

siderophores 11 • Anaero-

bic bacteria do not need to produce such iron-binding compounds, as they produce transport ligands that have a selective affinity for ferrous ion (Lankford, 1973}.
Many studies on experimental infection have shown that iron enhances
bacterial virulence (Weinberg, 1978; Bullen, 1981; Findelstein et al., 1983;
Hill, 1978; Bullen et al., 1968} in such strains as Pseudomonas aeruginosa,
Escherichia coli, Vibrio cholerae, Neisseria meningitidis, Neisseria gonorrhoeae, Bacteroides melaninogenicus and Staphylococcus aereus.
Bornside et al. (1968) have shown that both£. coli and hemoglobin are
necessary to produce lethal effect in infections of the peritoneal cavity.
Although

f.

coli is a common inhabitant of the gut, it usually is not regrad-

ed as a highly virulent pathogen.
as effective as hemoglobin with

They also found that lysed red cells were

I· coli in producing a lethal effect.

4

Bullen et al. (1968) further demonstrated that it is the iron in hemoglobin that is responsible for stimulating bacterial growth.
that

1·

coli

They reported

possess a binding site for the iron binding heme molecule from

which it gains selective growth advantage, when hemoglobin is available.
Based upon a number of clinical studies there is evidence of a correlation between the increase in the hemoglobin concentration in serum and susceptibility to infection.

Bullen (1981) concluded that it is the liberation

of heme compounds that can enhance clinical infections.
Gingival bleeding commonly accompanies gingivitis and periodontitis.
In such diseases the excess hemoglobin that was released could enhance the
virulence of the bacteria in the gingival sulcus.
Buhler and Muhlemann (1975) recorded the degree of gingivitis and collected the stimulated mixed saliva from 50 subjects, before and after a 10day period of intensified oral hygiene and measured the iron content in the
saliva.

They found that the use of methods to improve oral hygiene can re-

duce gingival inflammation and salivary iron content.

Gingival inflammation

was significantly but not strongly (r= 0.51) correlated with salivary iron
content.
Mukherjee (1985) measured the concentration of iron in crevicular fluid
from sites in gingivitis and periodontitis in human subjects.

The results

showed that the concentrations of iron in crevicular fluid collected from
periodontitis sites were significantly higher than those collected from
gingivitis sites (5.196 vs. 3.042 mg/L).

These concentrations (5.196 and

3.042 mg/L) were higher than the concentration in serum (about 1.26 mg/L) as

5

reported by Skypeck and Joseph (1981). Mukherjee concluded that this high
iron concentration in crevicular fluid might play an important role in the
growth and virulence of microorganisms of subgingival plaque and the initiation of active periodontitis.
Becraft et al. (1977) performed in vitro studies to investigate the
relationship between the administration of intramuscular iron-dextran for
prevention of iron deficiency and the susceptibility to

I· coli infection.

They found that an increased incidence of.£_. coli meningitis occurred after
iron-dextran treatment.

They reported in these cases the sepsis was due

to excess iron concentration in serum.

Excess iron causes inhibitory ef-

fects on leukocytes chemotaxis and markedly reduced bacteriostatic effects
against.£_. coli.
Bullen and Wallis (1977) also have demonstrated that such reversal of
the bactericidal effect of polymorphonuclear leukocytes occurs by a ferritin-antibody complex.

They found that there is no effect on abolishing

the bactericidal power of polymorphonuclear leukocytes by exposing them to
iron salts unless high concentrations of iron are used.

They further re-

ported that if the iron is presented in the form of a ferritin-antibody
complex it is readily phagocytosed by neutrophils, and that the introduction
of iron in this form, results in a viable bacterial count 346 times that of
the controls at 8 hours.
Sources of Lactoferrin
Lactoferrin was first described in bovine milk by Sorensen and Sorensen in 1939.

Johansson in 1958 found the similar iron-binding protein in
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human milk.

Montreuil et al. in 1960 described a method of isolating and

pruifying lactoferrin from human milk.
Biserte et al. in 1963 first demonstrated lactoferrin in sputum and
could not identify it in saliva.

They considered lactoferrin to be bron-

chial origin.
Using i11111unohistochemical method by staining sections of biopsy specimens with fluorescein-labelled antiserum against lactoferrin, Masson et
al. (1965, 1966) further demonstrated the presence of lactoferrin in all
bronchial glands.

Both serous and mucous cells appeared to be involved in

the production of lactoferrin.
Masson et al. (1965b) reported the same iron-binding protein in human
saliva.

A bronchial origin for the salivary lactoferrin is not at all im-

possible, since bronchial mucus is known to reach the pharynx owing to the
propulsory activity of the ciliated respiratory epithelium.

However, Masson

et al. (1966) have obtained further invnunohistochemical evidence for the
occurrence of lactoferrin in the salivary glands.
Masson et al (1966, 1966b) demonstrated that lactoferrin is present
in a large number of human secretions:

(1) respiratory secretions, e.g.

nasal and bronchial fluids; (2) tears; (3) secretions from the glandular
appendages of the digestive tract, e.g. saliva, bile and pancreatic juice;
(4) genital secretions, e.g. seminal fluid and cervical mucus and (5) urine.
The inmunohistological localization of lactoferrin in the mucosa of a
variety of normal human tissues was investigated using specific fluores.
ceinated antisera by Tourville et al. (1969). They found that the lactoferrin was much less ubiquitous in the epithelial cells of the various
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tissues studied and appeared to be restricted

pri~arily

to the acinar ep-

ithelium of the bronchial mucosa, parotid and submaxillary salivary glands
(serous acinar cells only}; and was also found in renal tubular cells.
Reitano et al. (1980} used an i11111unoperoxidase technique to study the
distribution of lactoferrin in human salivary glands from autopsy tissues.
Such tissues were fixed in Carnoy's fluid for the optimal preservation of
lactoferrin antigenicity.

They found that specific staining was seen in

the intralobular ducts of all salivary glands but never in the interlobular
ducts.

Also, acinar lactoferrin was detected in most serous demilunes of

the mixed glands and in some, but not all, acinar cells of the pure serous
glands.

However, no lactoferrin was detected in the acinar cells of the

pure mucous glands.

They also found that polymorphonuclear leukocytes were

the only additional cells containing lactoferrin in the oral tissues studied.
Moro et al. (1984} used an inmunofluorescence technique to examine the
distribution of lactoferrin in human minor salivary glands.

Lactoferrin was

found in serous acini, demilunes, intercalated and intralobular ducts.

They

concluded that in addition to major salivary glands and gingival crevicular
fluid, the minor salivary glands are also sources of lactoferrin in whole
saliva.

The reported findings cited above have created the impression that

lactoferrin is chiefly an epithelial secretion product.
Masson et al. (1968} studied the human uterine cervix and found that
lactoferrin originated from a particular cell type adjacent to the epithe1ium, possibly white cells.

Also, their investigations on guinea pig tis-

sues have shown that the spleen and bone marrow also are rich sources of
lactoferrin. They concluded that glandular epithelia are not the only
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sources of lactoferrin in mucosal and external secretions, but certain blood
cells may also be implicated in the production of this protein.
Masson et al. (1969) have demonstrated that lactoferrin is one of the
major proteins present in human and guinea pig neutrophilic polymorphonuclear leukocytes.

This identification was based on a comparison of its

electrophoretic, antigenic, and iron-binding properties with the corresponding properties of the same protein isolated from human and guinea pig milk.
Immunochemical quantitations showed that lactoferrin occurs in human neutrophil ic leukocytes at the concentration of 3 ug per 106 cells. Immunohistochemical data indicated that lactoferrin first appears in myeloid cells at
the stage of the promyelocyte.
Baggiolini et al. (1970) further demonstrated that the lactoferrin of
rabbit heterophil leukocytes has an intracellular distribution almost identical to that of alkaline phosphatase.

The parallelism between lactoferrin

and alkaline phosphatase was observed both in the sedimentation rate and in
equilibrium density.

They concluded that lactoferrin in the heterophil

leukocytes belongs to the same granules as does alkaline phosphatase.

They

are specific (secondary) granules in polymorphonuclear leukocytes.
Using direct and indirect immunofluorescent staining, Green et al.
(1971) found that lactoferrin was located in the nuclei and/or nuclear membrane of mature human polymorphonuclear neutrophilic leukocytes.
it is absent from lymphocytes, monocytes and eosinophiles.

However,

While Masson

et al. (1969) have reported that lactoferrin was located in the cytoplasm
of human polymorphonuclear leukocytes.

Green et al. explained the discrep-

ancy in the localization of lactoferrin in the nucleus and cytoplasm could
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be due to using different fixative and lactoferrin from different species.
Leffell and Spitznagel (1972) also found that lactoferrin is contained
in cytoplasmic granules of human polymorphonuclear leukocytes.

Upon centri-

fugation, it sediments in a band of granules that also contain 50% of the
lysozyme activity.

Their findings accorded with those of Masson et al. and

Baggiolini et al. (1970).
Properties of Lactoferrin
Lactoferrin has a single-chain.structure with the molecular weight
75,000 - 80,000 (Querinjean et al. 1971; Castellino et al., 1970).
molecule has two specific metal-binding sites.

Each

One bicarbonate ion will

bind tightly for each metal ion complexed to the protein (Masson and Heremans,
1968b).

Teuwissen et al. (1972) by means of a spectrophotometric titration
method, found that the binding of Fe 3+ by apolactoferrin or apotransferrin
involves three tyrosyl residues per metal ion.
Gordon et al. (1963) had determined the amino acid composition of
lactoferrin in bovine milk, and found that the basic character of the protein is evidenced by an excess per molecule of 27 cationic residues over
anionic residues.

Some investigators have insisted on the resemblance be-

tween lactoferrin and the iron-binding protein from serum, transferrin, because both proteins have a single-chain structure with the same molecular
weight (Querinjean, 1971). They also have the same metal-chelating properties, as both are able to bind two atoms of iron. For each Fe 3+ taken up,
one moleucle of bicarbonate is incorporated (Masson and Heremans, 1968b) and
three protons are released (Querinjean, 1971).

However, the two proteins
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appear to differ widely from one another, since no immunologic cross-reactivity has been demonstrated between serum transferrin and lactoferrin of
the same species (Montrenil et al., 1960; Blanc and Isliker, 1961). Amino
acid compositions have also failed to show similarities (Gordon et al.,
1963; Blanc et al., 1963).

Furthermore, the iron-binding sites of lacto-

ferrin are more stable at pH values below 4.0 than those of transferrin
(Johansson, 1960). Aisen and Leibman (1972) had shown that the binding constant for iron at pH 6.4 - 6.7, was 300 times larger for lactoferrin than
for transferrin.
The Function of Lactoferrin
It has been reported by Schade (1946) that iron-free serum transferrin
displays marked bacteriostatic effect on microorganisms.

In order to assess

whether lactoferrin has the similar properties, Masson et al. (1966b) performed a number of experiments in which solutions of lactoferrin of various
degrees of saturation with iron were tested for their inhibiting capacity.
They found a clear inhibitory effect by unsaturated lactoferrin on the Staphylococcus albus, Staphylococcus aureus and Pseudomonas aeruginosa. This inhibitory activity had disappeared when ferrous ammonium sulfate had been
added to the lactoferrin.

They suggested that iron-unsaturated lactoferrin

is bacteriostatic in action.
Reiten and Oram (1967) found that lactoferrin is very heat stable
(90°C for 60 minutes) but is inactivated by trypsin.

They also reported

that purified lactoferrin inhibited the growth of Bacillus stearothermophilus
and Bacillus subtilis and that its inhibitory activity is suppressed by

11
ferrous ions.
Oram and Reiter (1968) further extended their study and again have
shown that the bacteriostatic action of lactoferrin was suppressed by Fe 2+
2+
2+ .2+
2+
and enhanced by Zn ·' Co , N1 , and Cu .
Similar findings were reported by Kirkpatrick et al. (1971), by using
radial i11111unodiffusion method to measure the content of lactoferrin in parotid flui.ds and leukocytes from patients with chronic mucocutaneous candidiasis and normal subjects.

They found that there were no differences in

the concentrations of lactoferrin in the salivas from two groups.

The iron-

unsaturated protein markedly impaired replication of the yeast, and the
growth-inhibitory property was lost when lactoferrin was saturated with
iron.
Bullen et al. (1972) found that human milk with unsaturated iron-binding lactoferrin had a powerful bacteriostatic effect on Escherichia coli.
The bacteriostatic properties of milk were abolished if the iron-binding
proteins were saturated with iron.

They also studied guinea pig milk, and

found that newly born guinea pigs fed on an artificial diet and dosed with
E. coli had higher counts of E. coli in the intestine than normally suckled
animals.

They suggested that iron-binding proteins in milk may play an

important role in resistance to infantile enteritis caused by E. coli.
Reiter et al. {1975) found two strains of E. coli that were not inhibited by undiluted colostral whey or milk.

However, the colostral whey

became bacteriostatic for E. coli after dialysis or dilution in Kolmer
saline and the addition of precolostral calf serum or lactoferrin. The
lack of inhibition of E. coli in undiluted whey is due to the high
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concentration of citrate in colostral whey and milk.

It is suggested that

citrate competes with the iron-binding proteins for iron and makes the
citrate-iron complex available to the bacteria for growth.
Bishop et al. (1976) reported in their in vitro study that as little
as 0.02 mg of apo-lactoferrin per ml deionized distilled water in marked
inhibition of all mastitis-causing coliform bacteria.

Growth inhibition was

lost if iron-saturated lactoferrin or iron plus apo-lactoferrin was added to
the synthetic medium.

They also found that apo-lactoferrin at 20 mg/ml was

bactericidal for E.coli.

The addition of apo-lactoferrin plus citrate re-

sulted in loss of growth inhibition, however, the molar ratio (citrate to
apo-lactoferrin) was found to be more important than the absolute concentration of either component.

Because a ratio of 75 resulted in 50% growth in-

hibition of E.coli, whereas ratios of 300 and greater resulted in less than
10% growth inhibition.
The antimicrobial action of lactoferrin has been attributed to the
ability of depriving the essential iron.

And the reversibility of this an-

timicrobial effect, when an excess of iron is supplied to the nutritionally
deprived organisms, suggests a simple bacteriostatic effect for lactoferrin.
But Arnold et al. (1977) showed Streptococcus mutans and Vibrio cholerae,
but not Escherichia coli, were killed by incubation with purified human lactoferrin.

The resistance of E. coli to the bactericidal action of lacto-

ferrin in their study, could be due to the production of iron chelators
(enterochelins).

The ability to synthesize iron chelators has been sug-

gested as a significant virulence factor for several enteropathogenic strains
of E. coli. The investigation by Bullen et al. (1972) and Bishop et al.
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(1976) have suggested that synthesis of enterochelins allows the bacteria
to utilize lactoferrin.
Bullen and Annstrong (1979) reported rabbit polymorphonuclear leukocytes contain the iron-binding protein lactoferrin and can rapidly phagocytose and destroy Pseudomonas aeruginosa.

If the cells are exposed to a

ferritin-antibody complex, large amounts of this are phagocytosed by polymorphonuclear leukocytes and appear in the cytoplasmic granules and phagosomes. This leads to saturation of the cellular iron-binding protein with
Fe, the bactericidal power of the cells is greatly reduced with the result
that some phagocytosed bacteria survive and eventually grow and destroy
the cells.

An apoferritin-antibody complex used as a control is also phag-

ocytosed by polymorphonuclear leukodytes but has no effect on the bactericidal power of the cell.
Arnold et al.(1980) extended their study on bactericidal activity of
human lactoferrin.

The sensitivity of a variety of miroorganisms to human

lactoferrin was investigated.

Some of the microorganisms were clinical

isolates from 4-day supragingival plaque samples. They found that susceptible microorganisms includes Gram-positive and Gram-negative microbes, rods
and cocci, facultative anaerobes, and aerotolerant anaerobes.

Also, they

found organisms of the same species and even of the same strain can differ
in susceptibility to lactoferrin.

They suggested that accessibility of the

microorganisms to the lactoferrin target site may account for differences
in susceptibility.
Arnold et al. (1981) studied the influence of the metabolic state of
the bacteria, the incubation temperature, pH, and the presence of metal
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ions on the kinetics of killing Streptococcus mutans by lactoferrin.

They

found that after exposure to lactoferrin, a 15-minutes lag period occurred
before the initiation of killing, indicating that a two step process
volved in lactoferrin killing.

i~

in-

Cultures harvested during the early exponen-

tial phase were very sensitive to lactoferrin, whereas cultures harvested in
the early stationary phase were markedly more resistant.
killing was dependent on temperature.

Also, the rate of

At 37°C, there were no detectable

colony-forming units (CFU) after 1 hour of incubation.

However, when the

incubations were carried out at 23°C or at 4°C, the rate of killing was
markedly reduced.

Additionally, bactericidal activity was enhanced under

the slightly acid environment.

This indicated that the reduction of the

killing activity at neutral pH and the loss of killing under slightly alkaline condition might be due to the significant conformational changes of
lactoferrin that occur with increasing pH.

Furthermore, exogenous ferrous

or ferric ions did not reverse or prevent lactoferrin killing.
Arnold et al. (1982) compared the bactericidal effects of lactoferrin
on Streptococcus mutans with the bacteriostatic effects on iron deprivation.
They found that growth and macromolecular synthesis (DNA, RNA and protein)
were inhibited by incubation of S. mutans with purified human lactoferrin.
Their early studies (1980, 1981) have shown that lactoferrin binds to the
surface of susceptible bacteria, and this binding could result in the inhibition of growth by blocking some essential transport sites, resulting in
nutritional deprivation of the bacteria.

If this is true, then removal of

the surface-bound lactoferrin should reverse this inhibition.

But, in the

experiments (1982}, even after using a variety of washing agents to remove
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the bound lactoferrin from the cell surface, the viability could not be restored.

They concluded that this inhibition of metabolism and rapid loss

in viability observed with lactoferrin treatment suggest that lactoferrin
has a direct bactericidal effect on S. mutans that can not be attributed to
simple iron deprivation.

An alternative possible suggestion was that the

binding of lactoferrin to the bacterial cell surface triggers a second process that results in the irreversible cell death.
Oseas et al. (1981) found that PMNs released the

specifi~

granule pro-

duct lactoferrin more rapidly in response to chemotatic stimuli, which correlated with promotion of PMNs aggregation and enhanced PMNs adherence.
They suggested that PMN lactoferrin serves an autoregulatory role to retain
PMNs at inflanmatory sites to amplify the inflanmatory response.
Ambruso and Johnston (1981) reported that iron-saturated lactoferrin
from human colostrum and human neutrophils enhances the generation of the
bactericidal hydroxyl radical.

This product may result from the competetive

ability of lactoferrin to obtain iron from bacteria.

They suggested that

in addition to antimicrobial function, lactoferrin could play an important
role as regulator of hydroxyl radical production during phagocytosis.
Alteration of Lactoferrin Levels
Estevenon et al. (1975) used an inmunodiffusion technique to test the
presence of lactoferrin in the duodenal juice of patients with chronic calcifying pancreatitis (CCP).

They found that almost all patients with CCP

and 7% of control subjects without CCP have shown lactoferrin in duodenal
juice. They suggested that the lactoferrin test could have a certain value
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in the diagnosis of CCP, especially in the differential diagnosis between
CCP and other pancreatic diseases.
Colomb et al. (1976) further extended their study in 1975.

By using

the i1T1Tiunodiffusion techniques, lactoferrin was present in the pathological
pancreatic juice only.

However, when indirect ilTITlunofluorescence method was

used, the fluorescence was found in all samples, including normal pancreatic
tissue.

The difference between these two techniques were explained by the

different sensitivity and these results indicated that lactoferrin is a protein of pancreatic secretions.
Fedail et al. (1978) used radioimmunoassay to measure the concentration of lactoferrin in pure pancreatic juice from the patients with chronic
pancreatitis and control subjects.

They found that mean concentrations of

lactoferrin were 2310 mg/ml (range 870 - 11,4000) in the patients with chronic pancreatitis and 128 mg/ml (range 30 - 390) in control subjects.

They

suggested that the measurement of lactoferrin concentration in pure pancreatic juice may be useful in the diagnosis of pancreatic diseases.

Lacto-

ferrin seems is a sensitive marker of chronic pancreatitis because lactoferrin concentrations in pancreatic juice are specifically elevated in these
patients.
Harmon et al. (1975) determined the lactoferrin concentration in milk
by electroimmunodiffusion assay from normal lactating cows and cows with
mastitis.

They found that the mean concentration of lactoferrin in normal

group was 0.35 mg/ml.

In contrast, that found in the mastitis group from

0.55 mg/ml on day 1 to 1.89 mg/ml by day 3.

Harmon et al. (1976) also found

that experimentally induced Escherichia coli infection of bovine marrmary
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gland resulted in a 30-fold increase in lactoferrin concentration in mammary
secretion by_90 hours post-inoculation, and 4-fold increase in total daily
production of lactoferrin by 264 hours post-inoculation.

They suggested

that the increased lactoferrin production may be a result of a specific response of secretory tissue to inflammatory agents.
Tabak et al. (1978, 1978b) examined the levels of lactoferrin in the
parotid secretions of groups of patients (a) with chronic recurrent parotitis, (b) with complaints of dry mouth but no evidence of disease, (c) with
suspected or confirmed Sjogren's disease, (d) with sarcoidosis and (e) with
diabetes.

They found that lactoferrin values in parotid saliva during the

active phase of parotitis were elevated from two to twenty times normal.
The values for the recovery phase of parotitis were lower than in the active
phase, but still two to ten times normal.

Elevations in lactoferrin were

also noted in five of six patients with Sjogren's disease, but not in subjects with sarcoidosis, diabetes or "dry mouth" without sialographic changes.
In 1971, Kakizaki et al. reported a direct relationship between experimentally induced pancreatic disorders and alterations of histology and
function of the parotid glands.

Later, they developed a new test on parotid

saliva and emphasized the usefulness of the saliva test for the diagnosis of
pancreatic diseases (Kakizaki et al., 1976).
In order to find out if lactoferrin levels in parotid saliva are elevated in chronic pancreatitis, Durr et al. (1982) and Benini et al.· (1983)
measured the concentration of lactoferrin in parotid saliva from patients
with pancreatitis and controls.

They found that there was no difference in

the lactoferrin between these two groups.

They concluded that the elevation
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of lactoferrin concentration is confined to the exocrine pancreas and do
not affect salivary glands in chronic pancreatitis.
Fridman et al. (1983) using rocket immunoelectrophoresis to study the
•
concentrations of lactoferrin and lysozyme in the crevicular fluid from
patients with gingivitis, adult periodontitis, localized juvenile periodontitis and normals.

They found that lactoferrin in the normal group was sig-

nificantly lower than those in gingivitis group (0.63 vs. 1.5 ug/ul) but did
not show significant differences between gingivitis, adult periodontitis
and localized juvenile periodontitis.
Konttinen et al. (1984) studied the concentration of salivary lactoferrin in patients with Sjogren's syndrome by radioinvnunoassay.

The concen-

tration of lactoferrin in unstimulated mixed saliva in Sjogren's syndrome
group was 16.28

±

3.05 ug/mg of protein (range 7.42 - 33.64) and that in sex

and age matched normal group was 2.82
7.35).

±

0.82 ug/mg of protein (range 0.59 -

They demonstrated that by using the peroxidase-antiperoxidase stain-

ing method for labial salivary gland biopsy, a strong staining of lactoferrin was found in intralobular and interlobular ducts.

Their results indi-

cated that the concentration of unstimulated, mixed salivary lactoferrin is
a useful diagnostic tool for the diagnosis of Sjogren's syndrome.

They sug-

gested that abnormal salivary duct secretion and/or reabsorption is the
reason for high salivary lactoferrin values.
Muratsu and Morioka (1985), in order to study the mechanisms of increased susceptibility to oral infection in diabetics, examined the level
of salivary antibacterial factors; including lysozyme, lactoperoxidase and
and lactoferrin in diabetic hamsters. They found that although lysozyme
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activity decreased by 56% and lactoperoxidase activity decreased by 53% in
diabetic hamsters, there was no significant difference between the streptozotocin induced diabetic and non-diabetic hamsters in the amount of salivary
lactoferrin.

Also, before insulin treatment the ratio of lactoferrin to

total protein increased to double the amount of that of the control hamsters.
After the insulin treatment, the ratio of lactoferrin to total salivary protein reverted to nonnal values.
The Role of Bacteria in Gingivitis
Withdrawal of tooth-brushing in healthy human experimental subjects results in the accumulation of microbial plaque on the teeth and the development of gingivitis (Loe et al., 1965; Theilade et al., 1966).

If the bac-

terial plaque is removed by scaling, root planing and gingival curettage,
the gingivitis is reversible.

It indicates that bacteria are casually re-

lated in gingivitis (Krygier et al., 1973).
Listgarten (1976) in a study with the electron microscope found that
in healthy gingival sulcus a thin microbial layer approximately 60 um thick
adhered to the enamel surface of teeth.

The cells were predominantly coc-

coid in shape with a majority exhibiting cell wall features compatible with
those of Gram-positive microorganisms.
According to Socransky (1977), healthy periodontal tissues appear to
be associated with a scanty microbial flora that is located almost entirely
supragingivally on the tooth surface.

Microbial cell accumulations are

usually 1 to 20 cells in thickness and are composed mainly of Gram-positive
caecal fonns.
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The microorganisms commonly encountered in such sites include Streptococcus mitfs, Streptococcus sanguis, Staphylococcus epidennidis, Rothia
dentocariosa, Actinomyces viscosus, Actimyces naeslundii and occasionally
species of Neisseria and Veillonella (Listgarten, 1976; Listgarten et al.,
1975; Socransky et al., 1977; Slots, 1977).
According to Slots (1979), a scant microbial flora dominated by Grampositive microorganisms (85%), usually Streptococcus and facultative Actinomyces species is found in the healthy gingival sulcus.
In the gingivitis sites on teeth, Listgarten (1976) found that bacterial deposits appeared to be thicker than that found in the nonnal samples,
about 0.4 mm in thickness.

The bacterial samples comprised a wide variety

of microorganisms, including coccoid as well as filamentous fonns, and those
with Gram-positive and variety of Gram-negative cell wall patterns. Also,
flagellated bacteria and spirochetes were not uncommon in gingivitis samples.
According to Socransky (1977), in experimental gingivitis there is an
increase in the total mass of plaque and cell layers which often extend to
100 to 300 cells in thickness.

There is an increase in proportions of mem-

bers of the genus Actinomyces.

This group of microorganisms tends to be the

dominant genus associated with supragingival plaque, frequently comprising
50% or more of the isolates (Listgarten et al., 1975; Loesche and Syed, 1975;
Syed et al., 1975).

In long standing gingivitis, approximately 25% of the

microbial flora may be Gram-negative, including species of Veillonella, Vibro
(CampYlogacter) and Fusobacterium. The Gram-negative cells appear to be
located primarily on the surface of the bacterial plaque in subgingival
sites

(Listgarten, 1976; van Palenstein Heldennan, 1975).
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According to Slots {1979), the development of gingivitis is accompanied by a marked increased in the total number of Gram-negative microorganisms.

Fusobacterium nucleatum, Bacteriodes melaninogenicus

~·

inter-

medius, Haemophilus species, and other Gram-negative microorganisms comprised about 45% of the total gingivitis isolates.

Streptococcus and facul-

tative and anaerobic Actinomyces species constituted the majority of the
Gram-positive gingivitis isolates.
According to Page and Schroeder {1981), gingivitis and periodontitis
in man and other animals, without exception, is caused by bacteria.

How-

ever, the mere presence of bacteria, even the presence of specific pathogens is insufficient.

They emphasized that an interaction of bacteria with

the host's response systems is essential of the disease is to become established and progress.

This indicates that a healthy gingiva is the result

of an equilibrium between pathogenic factors from the gingival crevice flora
and the natural defense of the adjacent tissues.

If the nature of gingival

crevice flora alters either by an increase in the number of organisms or by
a shift to a more virulent bacterial population, the equilibrium might be
broken and inflanmation and destruction of tissues will follow.
Enzyme-linked Inmunosorbent Assay
Antibodies and antigens labeled with fluorescent dyes or isotopes
have been used extensively for inununodiagnosis over the past two decades.
However, they do have some disadvantages.

Inmunofluorescence, usually de-

pends on subjective assessment of the end result, is time-consuming and is
not easily automated so it can be used for only small batches of tests.
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Radioill1Tlunoassay is particularly suitable for large-scale operations but
the short shelf-life of the reagents, the expensive equipment, and because
it carries some risks, has tended to exclude radioill1Tlunoassay from many
small laboratories.

These considerations have led workers to search for

alternative labels for antiboides or antigens {Boller et al., 1976; Voller
et al., 1978).
Enzyme labeled reactants are safe, have long shelf life and yield
objective results with the same sensitivity as radioirnmunoassay, yet can
be used with relatively cheap, simple equipment.

According to Engvall

et

al. {1971), by using enzyme-linked irnmunosorbent assay {ELISA) 1 - 100 ng/ml
of the antigen could be determined.
The basic ELISA test depends on two assumptions:

(1) that antigen or

antibody can be attached to solid-phase support yet retain ill1Tlunological
activity and (2) that either antigen or antibody can be linked to an enzyme
and the complex to retain both immunological and enzymatic activity. According to Voller et al. {1976) the double antibody sandwich for detection of
11

11

antigen and the indirect method for detection of antibody are the most useful in practice.
It is clear from the work of Cantarero et al. {1980), Fields, et al.
{1983) and Kemeny et al. (1985) that inmobilization of proteins to plastic

material is dependent on the nature of the protein and the conditions used
for coating.

Kemeny et al. (1985) found that prolonged incubation of the

antibody with the plates resulted in an increased capacity for binding
antigen.

Also, the rate of antigen bound to the antibody-coated plates was
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much faster than that for the antibody alone bound to the plates, and the
amount of antigen bound to the antibody-coated plates did not increase
after 1 hour.
A serious problem limiting the measurement of specific antigen is the
high non-specific antibody binding to the plates.

Urbanek et al. (1985)

found that the rate of antigen bound to antibody-coated plates showed down
after 3 hours incubation while the non-specific binding increased progressively with longer incubation.

Also, the rate of this binding was higher

at 37°C than 21°C or 4°C, but this was largely due to increased non-specific
binding at this temperature.

They suggested that the best separation of

specific antibody binding from non-specific binding was to incubate the
plates at 4°C.
Thus, in this study we reduced the incubation time to 1 hour and reduced incubation temperatures to 4°C.

Also, we used 0.1% bovine serum al-

bumin (BSA) and 1% nonnal rabbit serum (NRS) as blocking agent. Also, Tween20 was included in all washing steps to prevent unspecific binding.

CHAPTER III
MATERIAL AND METHOD
Selection of Patients
Ten adult clinical patients with gingivitis, three females and seven
males, ranging in age from 20 to 31 were selected from the Department of
Periodontics, School of Dentistry, Loyola University of Chicago, based on
the following clinical criteria described by Listgarten in 1976:
val Index (GI): 2 - 3 ;

(2) Pocket depth less than 5 mm;

radiographic evidence of bone loss.

(1)

Gin~i

(3) Absence of

In addition, a group of age and sex-

matched clinically normal control subjects with healthy gingiva (3 females
and 7 males,

ranging in age from 23 to 31) were selected from dental stu-

dents at the School of Dentistry, Loyola University of Chicago.
None of the participants had received a prophylaxis within the last
six months.

They were not taking any medication and did not show any evi-

dence of systemic diseases or salivary gland diseases.

The female partici-

pants were neither pregnant nor taking oral contraceptives.
Pocket depth was measured to the closest millimeter by means of a
standard periodontal probe.

Bone loss was considered to be absent, meaning

that the alveolar crest is within 2 mm of cementoenamel junction(CEJ). The
severity of gingival inflammation was assessed by the criteria of the Gingival Index of Loe and Silness (1963) as modified by Loe (1967).

Four gingi-

val areas, buccal, lingual gingival margin and interdental papillae, of all
24
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teeth were given a score from zero to three as follows:
0:

normal (absence of inflammation)

1: mild inflammation (slight change in color, little change in
texture, no bleeding on probing.)
2.

moderate inflammation (moderate glazing, redness, edema
and/or hypertrophy, bleeding on probing.)

3.

severe inflammation (marked redness and edema, hypertrophy,
spontaneous bleeding or ulceration.)

The scores from the four areas of the tooth were added and divided by four
to give the GI for the tooth.

Finally, by adding the indices for the teeth

and dividing by the total number of teeth examined, the GI for the individual
was obtained.
Experimental Design
This study was reviewed by the chairman of the Loyola University Mediical Center Institutional Review Board for the Protection of Human Subjects
(IRB) before commencement.

At the baseline, after signing the consent form,

participants were given a clinical examination, and provided saliva samples
as subsequently described.
Patients with gingivitis received the following treatment:
giene instruction, scaling, root planing and gingival curettage.

oral hyIt took

four appointments, with a one week interval, to complete the treatment procedures.

Two weeks after the last appointment, the patients came back to

clinics for re-examination.
peated.

At this time, the baseline procedures were re-

for the control group._five weeks after the initial appointment
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the baseline procedures were repeated, and the study terminated.
-

Each subject brushed with water to remove plaque and residual debris
before saliva collection.

All participants spit saliva actively into a

funnel connected to a graduated centrifuge tube until 3 ml were obtained.
The collected saliva were clarified immediately by centrifugation at 3,675
rpm for ten minutes.

0.1% (about 3 mg) cetylpyridinium chloride (CPC) was

added to supernate, and the aggregated material in the supernate was removed.
The supernate samples were centrifuged at 3,675 rpm for ten minutes again.
The salivary supernatant then were frozen and stored for further tests, as
described by Olson et al. in 1985.
Experimental Design
At the baseline
(Clinical examination and saliva collection)

/

\

Experimental Group
appoiptment 1
.lt {l week)
appointment 2
(1 week)
appointment 3
(1 week)
appointment 4
(2 weeks)

Control Group

J
l

(5 weeks)

)
At the reexamination

~~~~~~~~-

(Clinical examination and saliva collection)
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ELISA Procedures
Quantitation of lactoferrin was perfonned by enzyme-linked inmunosorbent assay (ELISA) as described below (Dipaola and Mandel, 1980; Kemeny et
al., 1985; Urbanek et al.,' 1985):
1.

Tissue culture plates (American Scientific Products 24 - 2 ml
wells) were employed as solid phase.

2.

The wells were coated with specific antibody to lactoferrin by
passive adsorption and run in triplicate.

2 ml of rabbit anti-

human lactoferrin (Pel-Freez Biological) at concentration of
10 ug/ml in 0.05 MNa 2co 3 buffer (pH 9.6) were added to each
well.
3.

The coated wells were incubated at 4°C for overnight.

4.

The wells were washed four times to remove unbound antibody
with tris-buffered saline (TBS).

5.

The coated wells were then treated with 0.1% bovine serum albumin
and 1% normal rabbit serum in 0.05 MTBS at room temperature for
30 minutes.

6.

The wells were washed four times with TBS.

7.

2 ml of lactoferrin, prepared from human standard serum
(Calbiochem) at concentrations of 10.3 to 26.9 ng/ml in 0.05 M
TBS were added to triplicate wells to establish a

8.

stand~rd

2 ml of test saliva diluted 1:500 with 0.05 MTBS, pH 7.4
were added to the remaining wells.

9.

The plates were incubated at 4°C for 1 hour.

10.

The wells were washed four times with TBS.

curve.
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11.

2 ml of an enzyme-labeled preparation of the antibody, rabbit
anti-human lactoferrin-alkaline phosphatase {Pel-Freez Biological), diluted 1/200 with 0.05 MTBS and 0.2% BSA were added and
incubated at 4°C for 1 hour.

12. The wells were washed four times with TBS.
13.

2 ml of p-nitrophenyl phosphate, substrate, were added to each
well at the concentration of 1 mg/ml in 0.1 M Ethanolamine

{2-Aminoethanol) pH 9.6 containing 10 mM MgC1 2.
14. The wells were incubated at room temperature for 30 minutes.
15. 0.2 ml of 1 N NaOH were added to stop the enzyme reaction.
16.

150 ul solution from each well were transferred to Dynatech
plates containing 96 wells.

17. The optical density {OD) of each well was read with Minireader
II {Dynatech) at 410 nm.
18. The concentration of lactoferrin was determined by comparison
with a standard curve.
The ELISA procedures were performed twice, and the average concentration of each sample was obtained.

The values were analysed by the two sam-

ple student t test in order to establish a statistically significant difference between the two groups.

CHAPTER IV
RESULTS
Clinical Observations
Gingival Index (GI):
At the baseline, the gingival index for the experimental group was 1.8
± 0.2.

After the periodontal treatment, the GI was reduced to 1.2 ± 0.3

(Table 1).

This was significantly different at the level of 0.001 (Table 3).

For the control group, at the baseline and at the reexamination, the GI were
0.2

±

0.1 and 0.2

±

0.2 respectively (Table 2), and did not differ signifi-

cantly {Table 3).
Probing Pocket Depth:
At the baseline, the mean probing pocket depth was 2.5 ± 0.2
experimental group, and was 2.0
5).

±

lll11

for the

0.2 mm for the control group {Table 4 and

This was significantly different at the level of 0.001 {Table 6).

the reexamination, the mean probing pocket depth was 2.4
experimental group, and 2.0

±

±

At

0.2 mm for the

0.2 mm for the control group {Table 4 and 5).

This was significantly different at the level of 0.001 (Table 6).

However,

there was no significant difference between at the baseline and at the reexamination either in the experimental or control group (Table 6).
Lactoferrin Concentrations
The value for lactoferrin from unstimulated whole saliva from ten
29
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patients with gingivitis and ten clinically normal individuals, as quantitated by the double antibody sandwich ELISA technique, are shown in Table
7 and Table 8.
was 0.57
0.58

±

±

For the experimental group, at the baseline the mean value

0.08 mg%, after the periodontal treatment the mean value was

0.09 mg%.

There was no significant difference.

group, at the baseline the mean value was 0.56
ation the mean value was 0.55
ence.

±

0.15 mg%.

±

For the control

0.21 mg%, at the reexamin-

There was no significant differ-

Also, no significant differences were found between the experimental

and control groups either at the baseline or at the reexamination (Table 9).
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Table 1
Gingival Index tor the Experimental Group
At the
baseline

At the
reexamination

1
2

1.6

3
4
5
6
7

1.8
i.7
1.8
2.0
1.9
1.9
1.7
1.6

o.8
1.4
1.4
o.8
o.8
1.5
1.3
1.4
1.3
1.2

1.8

1.2

0.2

0.3

Patients

8

9

10
Mean
S.D.

2.i
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Table 2
Gingival Index tor the Control Group

Subjects
11
12
1.3
14
15
16
17
18
19
20

Mean
S.D.

At the
baseline

At the
reexamination

O.J

O.J

0.2
0.2

0.2
0 .3
0.2

o.o

o.o

0.5

0.5

O.J
0.2
o.o
0.2

o.4
0.1
o.o
0.2

0.2
0.1

0.2
0.2

O.J
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Table J
Gingival Index ( Mean .:t. S .D.),
comparison be~ween two groups
At the
baseline

At the
reexamination

t

Experimental Gr.

1.8 ±. 0.2

1.2 ± O.J

5.83

~0.001

Control Gr.

0.2 ±. 0.1

0.2 i 0.2

o.oo

N.S.*

* N.S.

= not

significantly different.

p
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Table 4
Probing Pocket Depth {mm) for the Experimental Group
At the
baseline

At the
reexamination

3

2.4
2.8
2.6

4

2.5

5

2.6

6
7
8

2.5

2.2
2.7
2.6
2.3
2.2
2.4

Patients
1

2

9
10

Mean
S.D.

2.6
2.3
2.7
2.4

2.5
0.2

2.5
2.3
2.6
2.3
2.4
0.2
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Table S
Probing Pocket Depth (mm) tor the Control Group
At the
baseline

At the
reexamination

12
13
14
15
16
17
18
19
20

2.0
1.9
2.2
2.1
2.0
2.2
2.1
2.0
1.7
2.2

2.0
1.9
2.2
2.1
2.0
2.2
2.1
2.0
1.7
2.2

Mean
S.D.

2.0
0.2

2.0
0.2

Subjects
11
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Table 6
Probing Pocket Depth (mean~ S.D., mm),
comparison between two groups
At the
baseline

At the
reexamination

t

p

Experimental. Gr.

2.5 ,!_ 0.2

2.4 :t 0.2

1.4J

N.S.*

Control Gr.

2.0 :!:. 0.2

2.0

:t. 0.2

O.OO

N.S.

*

t

7.14

p

~0.001

N.S.

= not

5.26
...( 0 .001

signi:t'icantly di:t':f'erent.
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Table 7
Lactoferrin

Concent~ations

(mg%) tor the Experimental Group

At the
baseline

At the
reexamination

2
J
4
5
6
7
8
9
10

0.51
0.53
o.68
0.69
0.51
0.53
0.52
o.68
o.46
0.59

0.46
o.49
0.58
0.54
0.63
0.77
0.56
0.58
0.57
o.64

Mean
S.D.

0.57
0.08

0.58
0.09

Patients
1
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Table 8
Lactoferrin Concentrations (mg%) for the Control Group
Subjects

At the
baseline

At the
reexamination

11
12
lJ
14
15

0.48
o.49
o.42
o.46
o.66

16

0.50

0.51
o.48
O.J8
o.47
0.61
0.58

17
18
19
20

o.46

0.52

o.44

o.48
0.94
o.48

Mean

s.n.

1.13
0.52
0.56
0.21

0.55
0.15
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Table 9
Lactoterrin Concentrations (mean ±. S.D.,
comparison between two groups
At the
baseline
Experimental Gr. 0.57 s.
Control Gr.

0.56

:t

At the
reexamination

t

o.oa

0. 58 :t- 0. 09

0.28

N.S.*

0.21

0.55 ± 0.15

0.125

N.S.

t

0.14

o.6

p

N.S.

N.S.

* N.S.

= not

~),

significantly different.

p

CHAPTER V
DISCUSSION
In the present study gingival tissues were assessed for the degree of
inflammation by the criteria of the Gingival Index System (Loe and Silness,
1963; Loe, 1967). ·The criteria include gingival tissues pale pink in color,
stippled in texture, firm in consistency, and in the absence of bleeding
upon probing is considered clinically normal.
gival Index score of zero.

This criteria received a Gin-

Gingival tissues displaying mild inflammation,

slight change in color, slight edema, no bleeding on probing, and received
a Gingival Index score one.

Gingival tissues displaying moderate inflamma-

tion, redness, edema and glazing, in the presence of bleeding upon probing,
and received a Gingival Index score of two.

Gingival tissues which displayed

severe inflammation, ulceration, and tendency to spontaneous bleeding received a Gingival Index score of three.
All participants in the control group were considered to be clinically
normal, while in the experimental group, the scores were changed from 1.8 at
the baseline to 1.2 at the reexamination.

This significant change was ap-

parently the result of the scaling, root planing, curettage and oral hygiene
instruction as performed in the protocol.
The experimental results reported in this study do show the presence
of lactoferrin in the whole saliva of the patients with gingivitis and in
clinically normal individuals as measured by the ELISA technique.
40
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Double antibody sandwich ELISA technique indeed can measure the contration of lactoferrin in the whole saliva.

However, the procedures used

in this study were modified by precipitation of salivary acid mucopolysaccharides with cetylpyridinium chloride (CPC) in the saliva processing.

CPC

is a good fixative for acid mucopolysaccharides (Williams and Jackson,
1956).

Since 1 - 100 ng/ml of the antigen can be determined by ELISA

(~ng

vall et al., 1971), ELISA is a very sensitive and useful method to measure
such small amount of lactoferrin in saliva.
The levels of lactoferrin in the saliva of the patients with gingivitis and individuals with clinically normal gingiva do not have significant
differences as determined by ELISA method.

This suggests that gingivitis

does not change the host's response with respect to the lactoferrin level
in saliva.

After the patients with gingivitis in this study received scal-

ing, root planing, gingival curettage and oral hugiene instruction, the
level of lactoferrin in their saliva did not change.

This suggests that

lactoferrin level in saliva does not respond to the treatment of gingivitis,
even when there is a significant clinical improvement in the gingival infla11111ation.
Also, in this study, the probing pocket depth in gingivitis group was
2.5

±

0.2 11111, and 2.0

±

0.2 11111 in control group (Table 4 and Table 5), it

does not suggest a similar effect in chronic periodontitis.

It is not known

whether there is any change of the level of lactoferrin in the saliva in the
patients with chronic periodontitis.

In such cases it is observed that

they show deeper probing pocket depth and more soft tissue and alveolar
bone destruction.

A study of salivary lactoferrin levels in patients with
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chronic periodontitis in order to assess any relevance and in comparison to
the findings-reported in this study should be done in the near future.
A previous study by Masson et al. (1966) reported the lactoferrin
values in stimulated parotid saliva as low as 0.2 to 0.3 mg% by the electrophoresis method.

Brandtzaeg (1971) reported lactoferrin concentration in

stimulated parotid saliva to be about 1 mg% and also noted that unstimulated salivary samples exhibited higher values than stimulated samples.
Tabak et al. (1978) used the rocket electrophoresis method and reported a range of 0.5 to 2 mg% lactoferrin in parotid saliva in their control subjects.
Dipaola and Mandel (1980) who also used the ELISA method reported the
lactoferrin value 0.81
0.54

±

±

0.36 mg% in the unstimulated parotid saliva and

0.26 mg% in the stimulated parotid saliva, in normal human subjects.

In their study, the saliva samples were diluted 1:25.

In our study the sali-

va samples were diluted 1:500, and indicates that our ELISA techniques is
more sensitive than that reported by Dipaola and Mandel.

This may be due to

the use of different buffer solution, incubation time and incubation temperature.
The sources of lactoferrin in human mouth has not been determined.
However, it could arise in part from disrupting polymorphonuclear leukocytes
and, in part, from epithelial cells that synthesize lactoferrin in the major
and minor salivary glands (Masson, 1968; Tabak et al., 1978).
The majority of salivary leukocytes continuously migrate into the
mouth through the gingival crevice (Wright, 1964; Schiott and Loe, 1970),
and 97 - 99% of them are neutrophils (Attstrom, 1970; Raeste, 1972). The
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lactoferrin concentrations found in the saliva of the patients with gingivitis and clinically normal individuals appear to be the same in this study.
This was unexpected as a three-fold increase in the number of leukocytes entering the gingival crevice had been observed during the course of gingivitis (Schiott and Loe, 1970; Attstrom and Egelberg, 1971). This increased
supply of lactoferrin could be balanced by the increased flow rate of gingival crevicular fluid in gingivitis (Attstrom and Egelberg, 1971; Alfano,
1974).
The saliva contains other antibacterial proteins.

Lactoferrin and

several other proteins in saliva have been identified as antibacterial agents, including secretory Ig A, the lactoperoxidase-thiocyanate-hydrogen
peroxide system, and lysozyme.

The concentration of each of these antibac-

terial agents alone may not be sufficient to influence the oral flora.
may need to act synergistically to accomplish that task.

They

Arnold et al.

(1979) found that although there was no significant difference in the lactoferrin values in saliva between the patients with inmune dysfunction and controls, the salivary concentrations of lysozyme and lactoperoxidase tend to
be elevated in the group of inmune deficient patients as compared to normal
controls.
There are apparently conflicting results in the measurements of salivary and sulcus fluid concentrations of antibacterial proteins.

Friedman

et al. (1983) found that lactoferrin in the crevicular fluid from the normal
group was significantly lower than those from gingivitis group (0.63 vs. 1.5
ug/ul), but there was no differences in the lysozyme concentrations between
these two groups.

van Palerstein Helderman (1976) found that there were no
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significant differences in lysozyme concentrations between normal subjects
and those with gingivitis.
Another important consideration in future studies of salivary antibacterial proteins was that of Olson et al. (1985) who found that the saliva of smokers contained lower concentrations of lactoferrin and greater concentrations of thiocyanate than the saliva in non-smokers, and no differences in lysozyme concentrations between these two groups.
It is uncertain at present whether the levels of the other antibacterial agents in saliva have been changed in the patients with gingivitis
or chronic periodontitis.
These observations may reflect differences in the methods used to
measure such proteins or variabilities in the salivary secretions of such
proteins in subjects with gingivitis and in smokers.
differences remain to be explained.

The reasons for such

CHAPTER VI
SUMMARY AND CONCLUSION
SUMMARY:
Ten adult clinical patients with gingivitis and ten clinically nonnal
age- and sex-matched control subjects were selected for measuring the concentrations of lactoferrin in saliva by using an enzyme-linked inmunosorbent
assay (ELISA) technique.

At the baseline, all participants were given a

clinical examination, and provided saliva samples.

Patients with gingivitis

then received the following treatment: oral hygiene instruction, scaling,
root planing and gingival curettage.

Approximately five weeks after the ini-

tial appointment, both patients with gingivitis and control subjects came back
for reexamination.

At this time, the baseline procedures were repeated, and

the study tenninated.
CONCLUSION:
(1) The experimental results reported in this study do show the presence of lactoferrin in the whole saliva of patients with gingivitis and
clinically nonnal individuals.
(2)

Double antibody sandwich ELISA technique is a very sensitive and

useful method to determine the concentration of lactoferrin in saliva.
(3)

The levels of lactoferrin in the saliva of patients with gingivi-

tis and individuals with clinically nonnal gingiva do not have significant
differences as detennined by ELISA technique.
45

This suggests_that gingivitis
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does not change the host's response with respect to the lactoferrin level
in saliva.
(4) After the patients with gingivitis in this study received scaling,
root planing, gingival curettage and oral hygiene instruction, the level of
lactoferrin in their saliva did not change.

This suggests that lactoferrin

level in saliva does not respond to the treatment of gingivitis, even though
there is a significant clinical improvement in the gingival inflanmation.
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